Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Arsenate reductase (ArsC) is an enzyme encoded by the arsC gene, found in bacteria such as *Escherichia coli* and *Staphylococcus aureus*. ArsC catalyzes the reduction of toxic arsenate (As(V)) to arsenite (As(III)), which can then be extruded from the cell. This reaction is a crucial component of prokaryotic resistance to arsenic compounds, allowing microorganism survival in arsenic-contaminated environments. The enzyme displays a unique protein fold and typically requires redox partners such as glutaredoxin or thioredoxin, depending on the bacterial species. ArsC is not directly targeted by any approved drugs, but inhibition could sensitize bacteria to arsenic toxicity, making it a possible target for environmental biotechnology or infectious disease control in specific organisms[1][2][3][4][5][6][7][8]. It is not linked to human disease outside of its environmental context.
Catalyzes the reduction of **arsenate (As(V))** to **arsenite (As(III))** through a glutaredoxin-dependent or thioredoxin-dependent pathway, enabling bacterial resistance to arsenate toxicity[1][2][3][4][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Arsenate reductase (ArsC).